Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach

Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach

ABSTRACT Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of providing flexible treatment regimens compatible with backgro...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahsan Rizwan, Hugh Giovinazzo, Tian Yu, Yuying Gao, Kun Wang, Fengyan Xu, Ya Wan, Jun Wang, Srikumar Sahasranaman, Marcia Campbell, Patrick Schnell, Ramil Abdrashitov, William D. Hanley, Nageshwar Budha
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Clinical and Translational Science
Subjects:
alternative dose
anti–PD‐1
exposure–response
immunotherapy
pharmacokinetics
pharmacometrics
Online Access:https://doi.org/10.1111/cts.70223
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70223

Similar Items